Genmab A/S (OTCMKTS:GNMSF) Sees Large Growth in Short Interest

Genmab A/S (OTCMKTS:GNMSF) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling 120,139 shares, an increase of 25.8% from the March 31st total of 95,479 shares. Approximately 0.2% of the company’s shares are sold short. Based on an average daily trading volume, of 81 shares, the days-to-cover ratio is currently 1,483.2 days.

Genmab A/S Price Performance

Shares of GNMSF stock opened at $255.33 on Friday. Genmab A/S has a 52-week low of $188.80 and a 52-week high of $352.00. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.01 and a current ratio of 2.02. The firm has a market capitalization of $15.72 billion, a P/E ratio of 16.49 and a beta of 0.94. The stock has a 50 day moving average price of $275.89 and a 200 day moving average price of $301.79.

Genmab A/S (OTCMKTS:GNMSF) last posted its quarterly earnings data on Tuesday, February 17th. The company reported $0.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.10 by ($2.55). Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. The business had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.05 billion.

About Genmab A/S

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.